Evidence map›Paper›PMID 36245876›Full record

ArticleFrontiers in psychiatry2022

Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs.

Eric Sparkes, Rochelle Boyd, Shuli Chen, Jack W Markham, Jia Lin Luo, Tahira Foyzun, Humayra Zaman, Charlotte Fletcher, Ross Ellison, Iain S McGregor and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 3 countries.

Eric SparkesThe Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Rochelle BoydThe Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Shuli ChenDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.
Jack W MarkhamThe Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Jia Lin LuoThe Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Tahira FoyzunMacquarie Medical School, Macquarie University, Sydney, NSW, Australia.
Humayra ZamanMacquarie Medical School, Macquarie University, Sydney, NSW, Australia.
Charlotte FletcherThe Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Ross EllisonClinical Toxicology and Environmental Biomonitoring Laboratory, University of California, San Francisco, San Francisco, CA, United States.
Iain S McGregorThe Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Marina J SantiagoMacquarie Medical School, Macquarie University, Sydney, NSW, Australia.
Felcia LaiFaculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, NSW, Australia.
Roy R GeronaClinical Toxicology and Environmental Biomonitoring Laboratory, University of California, San Francisco, San Francisco, CA, United States.
Mark ConnorMacquarie Medical School, Macquarie University, Sydney, NSW, Australia.
David E HibbsFaculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, NSW, Australia.
Elizabeth A CairnsThe Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Michelle GlassDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.
Adam AmetovskiThe Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Samuel D BanisterThe Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
University of Sydney · AUMacquarie University · AUUniversity of California, San Francisco · USUniversity of Otago · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synthetic cannabinoid receptor agonists (SCRAs) continue to make up a significant portion new psychoactive substances (NPS) detected and seized worldwide. Due to their often potent activation of central cannabinoid receptors

Indexed as

cannabinoid receptor 1 agonistscannabinoidsdockingin vitro evaluationpharmacologySCRAssynthesissynthetic cannabinoid

Identifiers

PMID36245876
PMCPMC9558907
OpenAlexW4297329504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.